These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17415017)

  • 1. Effect of Pueraria mirifica on vaginal health.
    Manonai J; Chittacharoen A; Theppisai U; Theppisai H
    Menopause; 2007; 14(5):919-24. PubMed ID: 17415017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women.
    Manonai J; Chittacharoen A; Udomsubpayakul U; Theppisai H; Theppisai U
    Menopause; 2008; 15(3):530-5. PubMed ID: 18202589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2004 Jan; 87(1):33-40. PubMed ID: 14971532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women.
    Suwanvesh N; Manonai J; Sophonsritsuk A; Cherdshewasart W
    Menopause; 2017 Feb; 24(2):210-215. PubMed ID: 27749740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA; Reape KZ; Wininger S; Hait H
    Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of Pueraria mirifica gel and of placebo gel on the vaginal microenvironment of postmenopausal women with Genitourinary Syndrome of Menopause (GSM).
    Sritonchai C; Manonai J; Sophonsritsuk A; Cherdshewasart W
    Maturitas; 2020 Oct; 140():49-54. PubMed ID: 32972635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
    Reed SD; Newton KM; LaCroix AZ; Grothaus LC; Grieco VS; Ehrlich K
    Menopause; 2008; 15(1):51-8. PubMed ID: 18257142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
    Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
    Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause.
    Warinsiriruk P; Tantitham C; Cherdshewasart W; Shobeiri SA; Manonai J
    Maturitas; 2022 Jun; 160():4-10. PubMed ID: 35550707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
    Freedman M; Kaunitz AM; Reape KZ; Hait H; Shu H
    Menopause; 2009; 16(4):735-41. PubMed ID: 19252451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study.
    Wuttke W; Gorkow C; Seidlová-Wuttke D
    Menopause; 2006; 13(2):185-96. PubMed ID: 16645532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements of vaginal atrophy without systemic side effects after topical application of Pueraria mirifica, a phytoestrogen-rich herb, in postmenopausal cynomolgus macaques.
    Jaroenporn S; Urasopon N; Watanabe G; Malaivijitnond S
    J Reprod Dev; 2014; 60(3):238-45. PubMed ID: 24748397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms.
    Virojchaiwong P; Suvithayasiri V; Itharat A
    Arch Gynecol Obstet; 2011 Aug; 284(2):411-9. PubMed ID: 20872225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.